Bookmarks
KEY FACTS
Terminology
Imaging
TERMINOLOGY
Definitions
- Alzheimer disease (AD)
- Progressive neurodegenerative brain disease generally characterized by impairments in episodic memory and other cognitive domains
- Likely related to β-amyloid (βA) and tau aggregation leading to synaptic dysfunction, neuronal/glial cell death
- Role of imaging
- Early detection of preclinical AD
- Diagnosis of AD with clinical presentation and other biomarkers
- Differential diagnosis between AD and other causes of dementia
- Mild cognitive impairment (MCI)
- Clinical symptoms of memory &/or other cognitive problems greater than normal for age and education
- Increased risk of conversion to AD, but not all progress to full dementia
- Annual conversion rate from MCI to dementia ~ 5-10%
- Pre-AD or pre-clinical AD
- Stage of disease process where series of pathologic events occurs in brain (e.g., βA plaque deposition) but prior to onset of significant clinically detectable symptoms
- Alzheimer disease (AD)
IMAGING
General Features
Nuclear Medicine Findings
MR Findings
Imaging Recommendations
DIFFERENTIAL DIAGNOSIS
PATHOLOGY
General Features
CLINICAL ISSUES
Presentation
Demographics
Treatment
DIAGNOSTIC CHECKLIST
Key Imaging Findings
Selected References
- Jagust W: Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci. 19(11):687-700, 2018
- Alzheimer's Association Report 2018 Alzheimer's disease facts and figures. https://www.sciencedirect.com/science/article/pii/S1552526018300414?via%3Dihub. Published May 2018. Accessed December 2019
- Rice L et al: The diagnostic value of FDG and amyloid PET in Alzheimer's disease-A systematic review. Eur J Radiol. 94:16-24, 2017
- Weidman DA et al: Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia. Neurocase. 23(1):41-51, 2017
- SNMMI Procedure Standard-EANM Practice Guideline for Amyloid PET. http://snmmi.files.cms-plus.com/ACNM/Documents/SNMMI-EANM%20Standard%20for%20Amyloid%20PET%20Imaging%20of%20the%20Brain%20.pdf. Published January 2016. Accessed December 2019
- Johnson KA et al: Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 9(1):e-1-16, 2013
- Hyman BT et al: National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 8(1):1-13, 2012
- Herholz K et al: Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 10(7):667-70, 2011
- McKhann GM et al: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3):263-9, 2011
Related Anatomy
Loading...
Related Differential Diagnoses
Loading...
References
Tables
Tables
KEY FACTS
Terminology
Imaging
TERMINOLOGY
Definitions
- Alzheimer disease (AD)
- Progressive neurodegenerative brain disease generally characterized by impairments in episodic memory and other cognitive domains
- Likely related to β-amyloid (βA) and tau aggregation leading to synaptic dysfunction, neuronal/glial cell death
- Role of imaging
- Early detection of preclinical AD
- Diagnosis of AD with clinical presentation and other biomarkers
- Differential diagnosis between AD and other causes of dementia
- Mild cognitive impairment (MCI)
- Clinical symptoms of memory &/or other cognitive problems greater than normal for age and education
- Increased risk of conversion to AD, but not all progress to full dementia
- Annual conversion rate from MCI to dementia ~ 5-10%
- Pre-AD or pre-clinical AD
- Stage of disease process where series of pathologic events occurs in brain (e.g., βA plaque deposition) but prior to onset of significant clinically detectable symptoms
- Alzheimer disease (AD)
IMAGING
General Features
Nuclear Medicine Findings
MR Findings
Imaging Recommendations
DIFFERENTIAL DIAGNOSIS
PATHOLOGY
General Features
CLINICAL ISSUES
Presentation
Demographics
Treatment
DIAGNOSTIC CHECKLIST
Key Imaging Findings
Selected References
- Jagust W: Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci. 19(11):687-700, 2018
- Alzheimer's Association Report 2018 Alzheimer's disease facts and figures. https://www.sciencedirect.com/science/article/pii/S1552526018300414?via%3Dihub. Published May 2018. Accessed December 2019
- Rice L et al: The diagnostic value of FDG and amyloid PET in Alzheimer's disease-A systematic review. Eur J Radiol. 94:16-24, 2017
- Weidman DA et al: Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia. Neurocase. 23(1):41-51, 2017
- SNMMI Procedure Standard-EANM Practice Guideline for Amyloid PET. http://snmmi.files.cms-plus.com/ACNM/Documents/SNMMI-EANM%20Standard%20for%20Amyloid%20PET%20Imaging%20of%20the%20Brain%20.pdf. Published January 2016. Accessed December 2019
- Johnson KA et al: Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 9(1):e-1-16, 2013
- Hyman BT et al: National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 8(1):1-13, 2012
- Herholz K et al: Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 10(7):667-70, 2011
- McKhann GM et al: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3):263-9, 2011
